Barclays analyst Balaji Prasad maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and raises the price target from $590 to $592.
Barclays Maintains Overweight on IDEXX Laboratories, Raises Price Target to $592
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.